Related Experiment Video
Updated: Jun 2, 2025

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
Rotavirus vaccine effectiveness and coverage among children younger than 5 years old in Shanghai, China: A
Xiaohuan Gong1, Zhuoying Huang2, Yaxu Zheng1
1Department of Epidemiology, School of Public Health, Fudan University, Shanghai, China; Division of Infectious Disease Control and Prevention, Shanghai Municipal Center of Disease Control and Prevention, Shanghai, China.
Insights
RotaTeq vaccine shows strong effectiveness against rotavirus diarrhea in children, while the Lanzhou lamb rotavirus vaccine offers partial protection. Rotavirus vaccine coverage in Shanghai is high and increasing.
Area of Science:
- Pediatrics
- Vaccinology
- Infectious Disease Epidemiology
Background:
- Limited post-marketing studies exist for Lanzhou lamb rotavirus vaccine (LLR) and RotaTeq in China.
- Rotavirus is a leading cause of severe diarrhea in young children globally.
Purpose of the Study:
- To assess the vaccine effectiveness (VE) of LLR and RotaTeq in Shanghai, China.
- To evaluate rotavirus vaccine coverage trends following RotaTeq licensure.
Main Methods:
- A test-negative case-control study using prospective surveillance in five Shanghai hospitals.
- Real-time RT-PCR used to confirm rotavirus infection in children aged 5 years and younger.
- Logistic regression models applied for matched and unmatched analyses.
Main Results:
- Partial LLR vaccination (2 doses) showed 49.09% VE against rotavirus diarrhea.
- Complete RotaTeq vaccination demonstrated robust VE (85.69%–89.46%) across analyses.
- Rotavirus vaccine coverage increased from 45.02% to 61.77% after RotaTeq licensure in 2018.
Conclusions:
- RotaTeq offers significant protection against rotavirus diarrhea in children.
- LLR provides moderate protection; complete vaccination is recommended.
- High rotavirus vaccine coverage in Shanghai suggests successful implementation; further research is needed for national policy.
Objectives:
The number of post-marketing studies assessing the vaccine effectiveness (VE) of the Lanzhou lamb rotavirus vaccine (LLR, licensed in 2000 exclusively in China) and the oral human attenuated pentavalent rotavirus vaccine (RotaTeq, licensed in China in 2018) in China is limited.
Methods:
A test-negative case-control study based on prospective surveillance was conducted among diarrhea patients aged 5 years and younger at five hospitals in Shanghai, China. Cases and controls were defined based on the results of real-time fluorescent quantitative reverse transcription polymerase chain reaction (rRT-PCR) of fecal samples for rotavirus. Both matched and unmatched case-control study designs were employed using logistic regression models, with adjustments for age at onset age and the rotavirus epidemic season.
Results:
In the LLR-specific analysis (247 cases, 2191 controls), the VE of partial LLR vaccination (2 doses) was 49.09 % (95 % CI: 1.69 % ∼ 73.64 %) in multivariate analyses. In the RotaTeq-specific analysis (42 cases and 523 controls), the VE of complete RotaTeq vaccination was 87.13 % (95 % CI: 45.87 % ∼ 96.94 %), 89.46 % (95 % CI: 55.03 % ∼ 97.53 %), and 85.69 % (95 % CI: 33.43 % ∼ 96.93 %) respectively in univariate, multivariate, and matched analyses, respectively. The vaccination coverage for any dose among 2893 patients with rotavirus-negative diarrhea born between 2011 and 2022 was 49.78 %. Following the licensure of RotaTeq in 2018, this coverage increased from 45.02 % to 61.77 %.
Conclusions:
RotaTeq demonstrates a robust protective effectiveness, while LLR provides a certain level of protection against mild to moderate rotavirus diarrhea in children in Shanghai. For privately purchased (non-NIP) vaccines, we estimate that the coverage for rotavirus vaccines among children in Shanghai is high. Complete rotavirus vaccination is recommended for age-eligible children. Further post-marketing research on rotavirus vaccines is necessary to inform decision-making regarding the introduction of rotavirus vaccination in China.
Related Concept Videos
Viral Mutations
Viral Recombination

